Imperial College Healthcare NHS Trust, St Mary's and Hammersmith Hospitals, Department of Obstetrics and Gynaecology, Praed Street, London W2 1NY.
University of Cambridge, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, Hills Road, Cambridge CB2 0QQ.
Maturitas. 2022 Jul;161:18-26. doi: 10.1016/j.maturitas.2022.01.012. Epub 2022 Feb 2.
To compare the difference between micronised progesterone (MP) and medroxyprogesterone acetate (MPA) in combination with transdermal oestradiol (t-E) on cardiovascular disease (CVD) risk markers in women diagnosed with an early menopause and premature ovarian insufficiency (EMPOI).
The European Society for Cardiology has identified carotid femoral pulse wave velocity (cfPWV) as the gold standard cardiogenic biomarker for risk stratification of arterial disease. Menopause has been shown to augment the age-dependent increase in arterial stiffness, with hormone replacement therapy (HRT) being the mainstay of management of women diagnosed with EMPOI.
A pilot randomised prospective open-label trial. Women were randomised to either cyclical MP (Utrogestan® 200mg) or MPA (Provera® 10mg) in conjunction with t-E (Evorel® Patches 50mcg/day) for 12 months. Seventy-one subjects were screened, and baseline data are available for 57 subjects.
Carotid-femoral pulse wave velocity (cfPWV).
PWV did not significantly change from baseline in either treatment arm. MP + t-E demonstrated a positive effect on traditional CVD markers, with a significant improvement seen in cardiac output (CO) (0.71±1.01mL/min, 95% CI 0.20 to 1.21) and reduction in diastolic blood pressure (DBP) (-3.43±6.31mmHg, 95% Cl -6.57 to -0.29) and total peripheral resistance (TPR) (-0.15±0.19mmHg⋅min⋅mL, 95% CI -0.24 to -0.05) after 12 months. MPA + t-E, in contrast, did not demonstrate significant changes from baseline in traditional haemodynamic parameters.
The positive changes in traditional markers were not reflected in the cardiogenic biomarker, cfPWV, which has demonstrated a higher positive predictive value for cardiovascular events than traditional measurements.
比较微粒化黄体酮(MP)和醋酸甲羟孕酮(MPA)联合经皮雌二醇(t-E)治疗早绝经和卵巢早衰(POI)女性心血管疾病(CVD)风险标志物的差异。
欧洲心脏病学会已将颈股脉搏波速度(cfPWV)确定为动脉疾病风险分层的金标准心脏生物标志物。绝经后动脉僵硬度随年龄增长而增加,激素替代疗法(HRT)是治疗 POI 女性的主要方法。
一项前瞻性随机开放标签试验。将女性随机分为周期性 MP(Utrogestan®200mg)或 MPA(Provera®10mg)联合 t-E(Evorel®贴剂 50μg/天)治疗 12 个月。共筛选了 71 例患者,其中 57 例患者有基线数据。
颈股脉搏波速度(cfPWV)。
两种治疗组的 PWV 与基线相比均无显著变化。MP+t-E 对传统 CVD 标志物有积极影响,心输出量(CO)显著增加(0.71±1.01mL/min,95%CI 0.20 至 1.21),舒张压(DBP)降低(-3.43±6.31mmHg,95%CI -6.57 至 -0.29),总外周阻力(TPR)降低(-0.15±0.19mmHg·min·mL,95%CI -0.24 至 -0.05),12 个月后。相比之下,MPA+t-E 治疗后传统血液动力学参数与基线相比无显著变化。
传统标志物的阳性变化并未反映在心脏生物标志物 cfPWV 中,cfPWV 对心血管事件的阳性预测值高于传统测量值。